Dynamic Technology Lab’s CRISPR Therapeutics CRSP Stock Holding History

Dynamic Technology Lab’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7,230	Closed	-$285K	–	1072
2024 Q4	$285K	Buy	+7,230	New	+$341K	0.05%	653
2024 Q2	–	Sell	-4,439	Closed	-$303K	–	1021
2024 Q1	$303K	Buy	+4,439	New	+$318K	0.03%	778
2023 Q3	–	Sell	-5,720	Closed	-$321K	–	1013
2023 Q2	$321K	Buy	+5,720	New	+$325K	0.04%	680
2022 Q2	–	Sell	-9,520	Closed	-$598K	–	1200
2022 Q1	$598K	Buy	+9,520	New	+$598K	0.07%	502
2020 Q1	–	Sell	-9,644	Closed	-$587K	–	1081
2019 Q4	$587K	Buy	+9,644	New	+$527K	0.09%	379
2019 Q2	–	Sell	-9,479	Closed	-$339K	–	1015
2019 Q1	$339K	Buy	+9,479	New	+$328K	0.06%	607

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dynamic Technology Lab's CRSP Position: Q1 2025 in Review

Dynamic Technology Lab sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 7,230 shares — an estimated $285K sold.

Dynamic Technology Lab first reported a position in CRSP in Q1 2019 and held it in 6 quarters. The position peaked at $598K in Q1 2022. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

Dynamic Technology Lab reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
Dynamic Technology Lab sold 7,230 CRISPR Therapeutics shares in Q1 2025, an estimated $285K.
Dynamic Technology Lab first reported a position in CRISPR Therapeutics in Q1 2019 and held it in 6 quarters.
Dynamic Technology Lab's CRISPR Therapeutics position peaked at $598K in Q1 2022.
396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Dynamic Technology Lab's 13F filing for Q1 2025, filed 16 May 2025.